Skip to main content

Table 3 CIN2+ case detection by different combinations of HPV testing methods and sampling media

From: Feasibility and accuracy evaluation of three human papillomavirus assays for FTA card-based sampling: a pilot study in cervical cancer screening

ID no.

Pathological result

HC2 (Rlu/PC)

careHPV™ (Rlu/PC)

Cobas® 4800

Liquid

FTA

Liquid

FTA

Liquid

FTA

447

CIN2

0.20a

181.73

0.42a

17.11

POS

POS

445

CIN2

99.90

22.42

51.31

28.50

POS

POS

444

CIN3

472.51

650.36

170.00

173.28

POS

POS

442

CIN2

675.40

325.26

117.93

140.85

POS

POS

448

CIN2

451.36

43.57

104.47

34.00

POS

POS

441

CIN2

2003.50

19.03

150.79

37.03

POS

POS

446

CIN2

4.26

0.28a

1.39

0.58a

POS

POS

443

CIN2

463.18

150.22

80.80

89.48

POS

POS

450

CIN2

1031.00

92.23

100.65

61.33

POS

POS

240

HCGIN

1.05

1.34

0.29a

0.78a

NEGa

NEGa

288

CIN3

26.62

1.42

20.65

3.71

POS

POS

344

CIN2

5.00

50.89

2.68

29.71

POS

POS

  1. CIN2 cervical intraepithelial neoplasia grade 2, CIN3 cervical intraepithelial neoplasia grade 3, HCGIN high grade cervical glandular intraepithelial neoplasia, FTA Whatman Indicating FTA Elute® card, HC2 Hybrid capture 2, NEG negative result, POS positive result, RLU/PC the ratio of relative light units to standard positive control, cut-point: 1.0
  2. aCIN2+ case failed to be detected